<DOC>
	<DOCNO>NCT02657616</DOCNO>
	<brief_summary>The central question study summarized follow : What stroke / death rate result use follow treatment strategy : anticoagulation vitamin-k-antagonists ( VKAs ) novel oral anticoagulant ( NOACs ) , anticoagulation VKAs anticoagulation NOACs ( ) . What thromboembolic complication rate result use treatment strategy ? What heavy bleeding rate result defined management strategy ? The analysis base data set patient atrial fibrillation ( AF ) ( 01/01/2010 - 30/06/2014 ) . 2010 used reference period 01/01/2011-30/06/2013 inclusion period . The minimum observation time per patient 12 month . Used data base AOK PLUS well AOK Baden-Württemberg AOK Bayern . The aim study compare clinical outcome different treatment strategy ( frequency event time first event ) . The influence alternative treatment strategy measure basis three different methodological approach : unadjusted comparison event council time first event define patient group ; matched-pair comparison ( propensity score match ) different group patient ( treatment strategy ) multivariate analysis use time event ( Cox proportional hazard model ) dependent variable .</brief_summary>
	<brief_title>Stroke Prophylaxis AF-patients : Real-life Effectiveness Safety Novel Anticoagulants Compared VKA</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>one inpatient two outpatient confirm diagnosis atrial fibrillation two different quarter Continuously insured AOK PLUS , AOK Bayern AOK BadenWürttemberg Age &lt; 18 year Maximum possible observational period &lt; 12 month ( exception : death )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>